insights_auto
Perspektīva: 73.3% garā pozīcija·6.7% īsā pozīcija
Pāriet uz analīzichevron_right
LILY34:BVMF
Eli Lilly and Company
195,67 R$
0,00%
(0,00) 1 d.
8. okt., 17:06:00 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: LILY34…
Atvērt
199,78 R$
Augsta
199,78 R$
Zema
188,60 R$
Tirgus kapitalizācija
1,10 trilj.
Vid. apjoms
36,66 tūkst.
Apjoms
62,64 tūkst.
Augstākā 52 ned.
223,07 R$
Zemākā 52 ned.
141,56 R$
Apgrozībā esošās akcijas
941,36 milj.
Darbinieku skaits
50 tūkst.
Atvērt
199,78 R$
Augsta
199,78 R$
Zema
188,60 R$
Tirgus kapitalizācija
1,10 trilj.
Vid. apjoms
36,66 tūkst.
Apjoms
62,64 tūkst.
Augstākā 52 ned.
223,07 R$
Zemākā 52 ned.
141,56 R$
Apgrozībā esošās akcijas
941,36 milj.
Darbinieku skaits
50 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Investing.com
·
pirms 6 stundām
Eli Lilly, Glaukos among market cap stock movers on Thursday
The Motley Fool
·
pirms 7 stundām
Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
Benzinga
·
pirms 9 stundām
Transcript: Eli Lilly Q2 2026 Earnings Conference Call
Zacks Investment Research
·
pirms 11 stundām
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
Profils
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Par “Eli Lilly and Company”
ĢenerāldirektorsDavid A. Ricks
Darbinieki50 tūkst.
Dibināšanas datums1876
Galvenais birojsIndianapolisa, Indiāna, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnelilly.com